TY - JOUR
T1 - Case definition and classification of leukodystrophies and leukoencephalopathies
AU - behalf of the GLIA Consortium
AU - Vanderver, Adeline
AU - Prust, Morgan
AU - Tonduti, Davide
AU - Mochel, Fanny
AU - Hussey, Heather M.
AU - Helman, Guy
AU - Garbern, James
AU - Eichler, Florian
AU - Labauge, Pierre
AU - Aubourg, Patrick
AU - Rodriguez, Diana
AU - Patterson, Marc C.
AU - Van Hove, Johan L.K.
AU - Schmidt, Johanna
AU - Wolf, Nicole I.
AU - Boespflug-Tanguy, Odile
AU - Schiffmann, Raphael
AU - van der Knaap, Marjo S.
N1 - Funding Information:
AV: Supported by grants from the National Institutes of Health , NINDS ( 1K08NS060695 ) and the Myelin Disorders Bioregistry Project . MCP: Funding: Actelion, National Institutes of Health, NINDS ( U54NS065768-02 ), National MS Society . Actelion Pharmaceuticals : Research grants; travel expenses; consulting honoraria directed to Mayo Clinic ; Genzyme (Sanofi): Consulting; Amicus: Data Safety Monitoring Board; Orphazyme (Denmark): Consulting; consulting honoraria directed to Mayo Clinic; Shire Human Genetic Therapies: travel expenses; consulting honoraria directed to Mayo Clinic; Stem Cells, Inc.: Chair, Data Monitoring Committee; honorarium retained; Up-To-Date: Section Editor; royalties retained; Journal of Child Neurology: Editorial Board (no compensation); WHO International Advisory Group on revision of ICD-10: ICNA representative (no compensation); IOM Committee to Review Adverse Effects of Vaccines: member (no compensation) — completed.
Funding Information:
The participation of MP and GH was supported by the Delman fund and the Neurogenetics Program at Children's National Health System. We would also like to thank Drs Yanick Crow and John Livingston for their valuable comments about Coats plus and CRMCC, and images of these disorders. The role of AV, GH and JL were supported by the Neurology Department at Children's National Health System and the Myelin Disorders Bioregistry Project. We also thank the Leukodystrophy Alliance for their support. GB has received a Research Scholar Junior 1 of the Fonds de Recherche du Québec en Santé (FRQS). She wishes to thank the Montreal Children's Hospital and McGill University Health Center Research Institutes, the RMAG (Réseau de Médecine Génétique Appliquée), the Fondation sur les Leucodystrophies, the Fondation du Grand Défi Pierre Lavoie, the Fondation Les Amis D'Élliot, the Fondation Désirée le Papillon, Genome Canada, and the Canadian Institutes of Health Research (CIHR) for financing her research on leukodystrophies.
Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Objective: An approved definition of the term leukodystrophy does not currently exist. The lack of a precise case definition hampers efforts to study the epidemiology and the relevance of genetic white matter disorders to public health. Method: Thirteen experts at multiple institutions participated in iterative consensus building surveys to achieve definition and classification of disorders as leukodystrophies using a modified Delphi approach. Results: A case definition for the leukodystrophies was achieved, and a total of 30 disorders were classified under this definition. In addition, a separate set of disorders with heritable white matter abnormalities but not meeting criteria for leukodystrophy, due to presumed primary neuronal involvement and prominent systemic manifestations, was classified as genetic leukoencephalopathies (gLE). Interpretation: A case definition of leukodystrophies and classification of heritable white matter disorders will permit more detailed epidemiologic studies of these disorders.
AB - Objective: An approved definition of the term leukodystrophy does not currently exist. The lack of a precise case definition hampers efforts to study the epidemiology and the relevance of genetic white matter disorders to public health. Method: Thirteen experts at multiple institutions participated in iterative consensus building surveys to achieve definition and classification of disorders as leukodystrophies using a modified Delphi approach. Results: A case definition for the leukodystrophies was achieved, and a total of 30 disorders were classified under this definition. In addition, a separate set of disorders with heritable white matter abnormalities but not meeting criteria for leukodystrophy, due to presumed primary neuronal involvement and prominent systemic manifestations, was classified as genetic leukoencephalopathies (gLE). Interpretation: A case definition of leukodystrophies and classification of heritable white matter disorders will permit more detailed epidemiologic studies of these disorders.
KW - Genetic leukoencephalopathy
KW - Glia
KW - Leukodystrophy
KW - Myelin
UR - http://www.scopus.com/inward/record.url?scp=84926245563&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84926245563&partnerID=8YFLogxK
U2 - 10.1016/j.ymgme.2015.01.006
DO - 10.1016/j.ymgme.2015.01.006
M3 - Review article
C2 - 25649058
AN - SCOPUS:84926245563
VL - 114
SP - 494
EP - 500
JO - Biochemical Medicine and Metabolic Biology
JF - Biochemical Medicine and Metabolic Biology
SN - 1096-7192
IS - 4
ER -